A recent development at the FDA has sparked a heated debate, raising legal and ethical concerns. The agency's new expedited drug program, championed by President Trump's administration, has caused alarm and confusion among staff. This program, known as the Commissioner's National Priority Voucher initiative, promises lightning-fast drug approvals, as little as one month, for medicines deemed to support U.S. national interests.
But here's where it gets controversial: traditionally, drug approvals have been handled by FDA review scientists and their supervisors, not political appointees. Yet, under this new program, drug reviewers are in the dark, and some are being told to skip regulatory steps to meet aggressive deadlines.
"The concept of doing a review in one to two months just doesn't have scientific precedent," says Dr. Aaron Kesselheim, a Harvard Medical School professor. "FDA cannot do the same detailed review in such a short time, and it doesn't have the resources to do so."
Reuters reported that FDA officials have delayed the review of two drugs in the program due to safety concerns, including a patient's death. Despite this, the program remains popular at the White House, where pricing concessions have been linked to FDA vouchers for drugmakers who agree to cut prices.
This has sparked widespread concern that FDA drug reviews, once objective, are now open to political interference. "It's extraordinary to have such an opaque application process, one that is obviously susceptible to politicization," says Paul Kim, a former FDA attorney.
Top FDA officials have declined to sign off on expedited approvals, citing legal and ethical concerns. The program hasn't been laid out in federal rules, and information is mostly confined to an agency website. Drugmakers can apply with a simple 350-word statement of interest.
Increasingly, agency leaders like Dr. Vinay Prasad, the FDA's top medical officer, have been contacting drugmakers directly about awarding vouchers, creating quandaries for FDA staff. The program has ballooned after outreach by FDA officials, initially framed as a pilot for five drugs, it now has 18 vouchers awarded, with more under consideration.
Under pressure from drugmakers, some FDA reviewers were told they can skip steps. Two people involved in the review of Eli Lilly's anti-obesity pill said company executives initially expected approval within two months, alarming FDA reviewers. The timeline didn't include the agency's standard 60-day prefiling period, which has been in place for over 30 years.
Lilly pushed for a quicker turnaround, and eventually, the agency and the company agreed to a two-week period. Staffers were pushed to keep the application moving, even with missing data, and were told by a senior FDA official that it was okay to overlook regulations if the science is sound.
Former reviewers and experts say this approach is the opposite of how FDA reviews should work. Skipping steps could also carry risks for drugmakers if future FDA leaders decide a drug wasn't properly vetted.
"They are fundamentally changing the application of the standards, but the underlying law remains," says Kesselheim. "The hope is that one day we will return to these scientifically and legally sound principles."
This development highlights the delicate balance between expediting drug approvals and maintaining scientific integrity and public safety.
